HERPESVIRUS VACCINES

Authors    Petrini S, Maple P

Abstract    The Special Issue titled “Herpesvirus Vaccines” contains different articles and a review regarding veterinary and human herpesviruses. The Special Issue covers topics including Bovine alphaherpesvirus 1 (BoHV-1), Infectious laryngotracheitis virus (ILTV), Equine alphaherpesvirus 1 (EHV-1), Equine alphaherpesvirus 4 (EHV-4), Human Cytomegalovirus virus (HCMV), and Epstein–Barr virus (EBV). The open manuscript by Petrini et al. [1] suggests the urgency of developing strategies to eradicate Bovine alphaherpesvirus 1 (BoHV-1) in both cattle and water buffalo species. To date, in Europe, glycoprotein E (gE)-deleted marker vaccines against BoHV-1 are commercially available only for the cattle industry. For the first time, the manuscript evaluates the safety and efficacy of a commercial inactivated gE-deleted marker vaccine (Bovilis ®® IBR marker inactivatum, Intervet International B.V. Boxmeer, Holland) in water buffalo. Ten water buffaloes were divided into two groups (A = vaccinated; B = controls) with five animals each. The only animals in group A were injected via intramuscular route. Sixty days after the first immunization, all animals were challenged with a wild-type BoHV-1 strain via the intranasal route. The BoHV-1 immune response was detected in group A 30 days post-vaccination, whereas the antibodies appeared 10 days post-challenge in group B. Moreover, group A did not demonstrate viral shedding or clinical signs, unlike group B. However, post-challenge, the BoHV-1 humoral and cell-mediated immune responses increased more dramatically in group A compared to group B. In conclusion, the results of this study indicate that the vaccination of Bubalus Bubalis, with the above-mentioned product, was able to protect the water buffaloes against wild-type BoHV-1 strain. Finally, the buffalo’s marker vaccine can be used under the new European Regulations, so-called “Animal Health Law”, which can control BoHV-1 in cattle and Bubalus Bubalis.

Publish Date   2022

Volume   10 (4)

ISSN    2076-393X

DOI     doi.org/10.3390/vaccines10040628

URL    https://www.mdpi.com/2076-393X/10/4/628

Journal    Vaccines, special issue "Herpesvirus Vaccines”

Pages   Article no. 628

PMID   35455377